Zenas BioPharma (ZBIO) Stock Price, News & Analysis

Company Overview

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

Key Stats

• Today's Range: $9.11 to $9.80
• 50-Day Range: $8.68 to $12.11
• 52-Week Range: $5.83 to $26.25
• Volume: 260,125 shs
• Average Volume: 205,508 shs
• Market Capitalization: $382.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $36.67
• Consensus Rating: Buy

Zenas BioPharma Stock Analysis - MarketRank™

Zenas BioPharma scored higher than 36% of companies evaluated by MarketBeat, and ranked 761st out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Zenas BioPharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Zenas BioPharma has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Zenas BioPharma is -2.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Zenas BioPharma is -2.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Zenas BioPharma has a P/B Ratio of 1.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ZBIO.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Zenas BioPharma does not currently pay a dividend.

Dividend Growth

Zenas BioPharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for ZBIO.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 1.81

News Sentiment

Zenas BioPharma has a news sentiment score of 1.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Zenas BioPharma this week, compared to 14 articles on an average week.

Search Interest

Only 1 people have searched for ZBIO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Zenas BioPharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.50% of the stock of Zenas BioPharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

ZBIO Stock Analysis - Frequently Asked Questions

How have ZBIO shares performed this year?

Zenas BioPharma's stock was trading at $7.90 at the beginning of the year. Since then, ZBIO stock has increased by 15.7% and is now trading at $9.14.
View the best growth stocks for 2025 here.

How were Zenas BioPharma's earnings last quarter?

Zenas BioPharma, Inc. (NASDAQ:ZBIO) announced its quarterly earnings data on Thursday, May, 15th. The company reported ($0.80) earnings per share for the quarter, beating analysts' consensus estimates of ($1.15) by $0.35. The company earned $10 million during the quarter, compared to analyst estimates of $5 million.

When did Zenas BioPharma IPO?

Zenas BioPharma (ZBIO) raised $225 million in an IPO on Friday, September 13th 2024. The company issued 13,235,294 shares at $17.00 per share.

How do I buy shares of Zenas BioPharma?

Shares of ZBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Zenas BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Zenas BioPharma investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Trade Desk (TTD), Advanced Micro Devices (AMD), Biosig Technologies (BSGM), Ford Motor (F) and Genius Sports (GENI).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 7/01/2025
• Next Earnings (Estimated): 8/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ZBIO
• Previous Symbol: NASDAQ:ZBIO
• CIK: 1953926
• Web: N/A
• Phone: (857) 271-2954
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $36.67
• High Stock Price Target: $45.00
• Low Stock Price Target: $30.00
• Potential Upside/Downside: +301.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.47
• Quick Ratio: 6.47

Sales & Book Value

• Annual Sales: $5 million
• Price / Sales: 76.47
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.48 per share
• Price / Book: 1.22

Miscellaneous

• Outstanding Shares: 41,830,000
• Free Float: 34,931,000
• Market Cap: $382.33 million
• Optionable: N/A
• Beta: N/A